Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma
Braz. j. infect. dis
; 7(2): 111-120, Apr. 2003. tab
Artigo
em Inglês
| LILACS
| ID: lil-351154
Biblioteca responsável:
BR1.1
RESUMO
BACKGROUND:
The empirical use of antibiotic treatments is widely accepted as a means to treat cancer patients in chemotherapy who have fever and neutropenia. Intravenous monotherapy, with broad spectrum antibiotics, of patients with a high risk of complications is a possible alternative.METHODS:
We conducted a prospective open-label, randomized study of patients with lymphoma or leukemia who had fever and neutropenia during chemotherapy. Patients received either monotherapy with ticarcillin/clavulanic acid (T) or ceftriaxone plus amikacin (C+A).RESULTS:
Seventy patients who presented 136 episodes were evaluated, 68 in each arm of the study. The mean neutrophil counts at admission were 217cells/mm (T) and 201cells/mm (C+A). The mean duration of neutropenia was 8.7 days (T) and 7.6 days (C+A). Treatment was successful without the need for modifications in 71 percent of the episodes in the T group and 81 percent in the C+A group (p=0.23). Treatment was considered to have failed because of death in two episodes (3 percent) in the T group and three episodes (4 percent) in the C+A group, and because of a change in the drug applied in one episode in the T group and two episodes in the C+A group. Overall success was 96 percent (T) and 93 percent (C+A). Adverse events that occurred in group T were not related to the drugs used in this study.CONCLUSION:
In pediatric and adolescent patients with leukemia or lymphoma, who presented with fever and neutropenia, during chemotherapy, ticarcillin/clavulanic acid was as successful as the combination of ceftriaxone plus amikacin. It should be considered an appropriate option for this group of patients at high risk for infections
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Contexto em Saúde:
ODS3 - Saúde e Bem-Estar
/
ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis
/
ODS3 - Meta 3.2 Reduzir as mortes de recém nascidos e crianças com menos de 5 anos
Problema de saúde:
Meta 3.2: Reduzir as mortes de recém nascidos e crianças com menos de 5 anos
/
Leucemia
/
Linfomas e Mieloma Múltiplo
/
Outras Doenças Sanguíneas
/
Doenças Não Transmissíveis
Base de dados:
LILACS
Assunto principal:
Ticarcilina
/
Linfoma não Hodgkin
/
Leucemia
/
Ácidos Clavulânicos
/
Quimioterapia Combinada
/
Febre
/
Neutropenia
Tipo de estudo:
Ensaio clínico controlado
/
Estudo de etiologia
/
Estudo observacional
/
Estudo prognóstico
/
Fatores de risco
Limite:
Adolescente
/
Criança
/
Criança, pré-escolar
/
Feminino
/
Humanos
/
Lactente
/
Masculino
País/Região como assunto:
América do Sul
/
Brasil
Idioma:
Inglês
Revista:
Braz. j. infect. dis
Assunto da revista:
Doenças Transmissíveis
Ano de publicação:
2003
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Federal University of São Paulo/BR